SeeWolfS. M., “Shifting Paradigms in Bioethics and Health Law: The Rise of a New Pragmatism,”American Journal of Law & Medicine20 (1994): 395–415, at 395–396, and note 2.
2.
See, e.g., American Bar Association Center for Professional Responsibility, Model Rides of Professional Conduct (2003).
3.
SeeJohnsonS. H., “Five Easy Pieces: Motifs of Health Law,”Health Matrix14 (2004): 131–140, at 133–135.
4.
See 45 C.F.R. § 46.107(a).
5.
SeeWilsonR. F., “Hospital Ethics Committees As The Forum of Last Resort: An Idea Whose Time Has Not Come,”North Carolina Law Review76 (1998): 353–406, at 355 and note 5.
OIG Draft Supplemental Compliance Program Guidance for Hospitals, Federal Register69: 32,012, 32,030 (June 8, 2004) (emphasis added).
11.
See 42 U.S.C. § 1320a-7b(b).
12.
See 31 U.S.C. § 3729(a) (statutory penalties); 28 C.F.R. § 85.3(a)(9) (increasing penalties for inflation); 42 U.S.C. § 1128(b) (permitting permissive exclusion of health care providers).
13.
SeeKrauseJ. H., “Health Care Providers and the Public Fisc: Paradigms of Government Harm Under the Civil False Claims Act,”Georgia Law Review36 (2001): 121–217, at 202–06 (2001) (discussing problems created by mass settlement of FCA allegations); ReinhardtU. E., “Medicare Can Turn Anyone Into a Crook,”Wall Street Journal, Jan. 21, 2000, at A18 (“Rather than engaging in a long, protracted fight to set the record straight, throughout which share prices suffer and business slumps, a health company's best bet may simply be to hand over the fines and get on with business”)
14.
SeeKrause, supra note 13, at 205–06.
15.
31 U.S.C. § 3730(d) (discussing awards to qui tam plaintiffs).
16.
31 U.S.C. § 3730(h) (protecting employees who are “discharged, demoted, suspended, threatened, harassed, or in any other manner discriminated against” due to their protected FCA-related activities).
17.
See, e.g., X Corp. v. Doe, 805 F. Supp. 1298 (E.D. Va. 1992) (granting preliminary injunction to employer to prevent former counsel from disclosing allegedly confidential company information, taken in support of potential qui tam suit against company).